ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Chronic pain caused by nerve damage is tough to treat because its underlying mechanisms aren't well-understood. But new findings by researchers at Harvard Medical School offer hope for those who suffer from this neuropathic pain. Ru-Rong Ji and colleagues report that matrix metalloprotease (MMP) enzymes involved in cellular remodeling and inflammation are also part of the pain process (Nat. Med., DOI: 10.1038/nm1723). Tests in rats and mice showed that nerve damage transiently increases production of MMP-9 in neurons and subsequently increases production of MMP-2. The team also found the MMPs wreak havoc by cleaving interleukin-1β and activating microglia and astrocytes, which have all previously been implicated in the pain process. Inhibiting MMP-9 blocks an early phase of pain associated with nerve injury, and blocking MMP-2 suppresses a late phase of pain. According to the researchers, the results suggest that inhibition of the MMP enzymes could "provide a novel therapeutic approach for the treatment of neuropathic pain."
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter